. Am J Gastroenterol 2008; 103: 2694–9

44. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100: 1184–7.

45. Clegg DJ, Brown LM, Woods SC, et al. Gonadal hormones determine sensitivity to central leptin and insulin.Diabetes 2006; 55: 978–87.

46. Quinton ND, Smith RF, Clayton PE, et al. Leptin binding activity changes with age: the link between leptin and puberty. J Clin Endocrinol Metab 1999.

47. Asarian L, Geary N. Cyclic estradiol treatment normalizes body weight and restores physiological patterns of spontaneous feeding and sexual receptivity in ovariectomized rats.Horm Behav 2002; 42: 461–71.

48. Howard JM, Beddy P, Ennis D, et al. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma.Br J Surg 2010; 97: 1020–7.

49. Quinton ND, Laird SM, Okon MA, et al. Serum leptin levels during the menstrual cycle of healthy fertile women.Br J Biomed Sci 1999; 56: 16–9.

50. Ainslie DA, Morris MJ, Wittert G, et al. Estrogen deficiency causes central leptin insensitivity and increased hypothalamic neuropeptide Y. Int J Obes Relat Metab Disord 2001; 25: 1680–8.

51. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett’s esophagus.Gastroenterology 2007; 133: 403–11.

52. Lagergren J, Nyrén O. Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients.Cancer Epidemiol Biomarkers Prev 1998; 7: 913–5.

53. Rudolf Kaaks, Annekatrin Lukanova and Mindy S. Kurzer Obesity, Endogenous Hormones and Endometrial Cancer,Cancer Epidemiol Biomarkers Prev 2002; 11: 1531–1543.

54. Frederic Amant, Philippe Moerman, Prof Patrick Neven, Dirk Timmerman, Erik Van Limbergen, Ignace Vergote. Endometrial cancer, The Lancet: volume 366, Issue 9484, 6–12 August 2005, Pages 491–505.

55. Luigino Dal Maso, Livia S. A. Augustin, Aspasia Karalis, Renato Talamini, Silvia Franceschi, Dimitrios Trichopoulos, Christos S. Mantzoros, and Carlo La Vecchia. Circulating Adiponectin and Endometrial Cancer Risk, JCEM: Volume 89 Issue 3 – March 1, 2004.

56. MacInnis RJ. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 989–1003.

57. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort.Cancer Epidemiol Biomarkers Prev 2007; 16: 63–9.

58. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675–84.

59. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977–83.

60. Yin Cao1, Jing Ma2. Body Mass Index, Prostate Cancer – Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res April 2011 4; 486.

61. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.

62. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366–81.

63. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers